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Introduction
============

As nascent polypeptides enter the ER lumenal space, N-linked glycans modify asparaginyl residues in the context Asn-Xaa-Ser/Thr ([@bib28]). This is catalyzed by oligosaccharyltransferase (OT), which transfers a preformed oligosaccharide unit, glucose~3~mannose~9~GlcNAc~2~ (G~3~M~9~Gn~2~), from the lipid-linked oligosaccharide (LLO) glucose~3~mannose~9~ N-acetylglucosamine~2~-P-P-dolichol (G~3~M~9~Gn~2~-P-P-Dol). Synthesis of G~3~M~9~Gn~2~-P-P-Dol starts with dolichol-P (Dol-P), and sequentially requires 2 residues of GlcNAc from UDP-GlcNAc (the first transfer also forming the pyrophosphate linkage), 5 residues of mannose from GDP-mannose, 4 residues of mannose from mannose-P-Dol (synthesized from Dol-P and GDP-mannose), and 3 residues of glucose from glucose-P-Dol (synthesized from Dol-P and UDP-glucose). During biosynthesis, Dol-P and G~3~M~9~Gn~2~-P-P-Dol are oriented at the cytoplasmic and lumenal faces, respectively, of the ER membrane, with flipping of the key intermediate M~5~Gn~2~-P-P-Dol ([@bib48]; [@bib23]). Upon transfer of G~3~M~9~Gn~2~ by OT, Dol-P-P is released, and is recycled to Dol-P for additional rounds of glycosylation ([@bib39]).

N-linked G~3~M~9~Gn~2~ is sequentially digested by ER glucosidases and mannosidases to generate high-mannose processing intermediates with functions in protein folding, quality control, and degradation ([@bib38]; [@bib1]). Inhibition of LLO synthesis by tunicamycin, accumulation of LLO intermediates such as M~2-6~Gn~2~-P-P-Dol caused by glucose deprivation, mutations affecting mannosyl precursor synthesis, and interference with ER-processing glycosidases all disturb ER homeostasis ([@bib32]). To minimize damage, mitigate the source of stress, and restore ER homeostasis to normal, the resulting ER stress activates a set of coordinated signals known collectively as the unfolded protein response (UPR). UPR signaling uses resident ER membrane proteins with lumenal stress-sensing domains that control activation of their respective cytoplasmic effector domains ([@bib41]). Of particular significance here, the cytoplasmic domain of the stress-sensor PKR-like ER kinase (PERK; [@bib19]), also termed PEK ([@bib49]), is a kinase activated by transautophosphorylation that phosphorylates eukaryotic initiation factor (eIF)-2α. The resultant eIF2α-P interferes with translation initiation, which is sufficient to inhibit protein synthesis by 70--90% after robust ER stress. Importantly, translation attenuation by PERK reduces stress by diminishing the load of ER client protein ([@bib21]).

Several lines of evidence suggest that metabolic deficiencies affecting G~3~M~9~Gn~2~-P-P-Dol synthesis or N-linked glycosylation might be compensated for by ER stress responses, implying homeostatic adaptation ([@bib32]). The goal of this study was to investigate the potential role of PERK in such adaptation. To do so, we took advantage of the fact that, for many cell types normally maintained in physiological (≥4 mM) glucose, brief incubations with 0.3--0.5 mM glucose hinder conversion of undermannosylated LLO intermediates to G~3~M~9~Gn~2~-P-P-Dol. This is distinguished from the glucose-starvation effect, which requires glucose-free medium and causes a rather discrete shift from G~3~M~9~Gn~2~-P-P-Dol to M~5~Gn~2~-P-P-Dol ([@bib4]). We focused on our prior finding that dermal fibroblasts incubated 20 min in medium with 0.5 mM glucose accumulated M~2-6~Gn~2~-P-P-Dol. Although the improperly glycosylated proteins that resulted were expected to compromise ER function, the treatment by itself was too brief to activate an ER stress response. Significantly, ER stress induced by dithiothreitol (DTT), thapsigargin (TG), castanospermine, azetidine-2-carboxylic acid, or geldanamycin all restored G~3~M~9~Gn~2~-P-P-Dol levels in the fibroblasts to normal ([@bib8]; [@bib42]). The underlying mechanism was not determined, although regulated glycogenolysis was later proposed ([@bib16]). The brief treatments used argued against considerable contributions of UPR transcriptional programs ([@bib41]).

In this study, we identify a surprisingly simple protective mechanism by which the ER stress response modulates G~3~M~9~Gn~2~-P-P-Dol synthesis and N-linked glycosylation. It is known that ER stress from aberrant G~3~M~9~Gn~2~-P-P-Dol production activates PERK. PERK is shown to reduce LLO consumption by attenuating synthesis of glycoprotein precursor polypeptides. This facilitates extension of undermannosylated intermediates to G~3~M~9~Gn~2~-P-P-Dol, restoring correct N-linked glycosylation. In this way, PERK balances glycoprotein synthesis with LLO flux.

Results
=======

Evaluation of G~3~M~9~Gn~2~-P-P-Dol synthesis
---------------------------------------------

Most mammalian cells in conventional media containing physiological glucose concentrations synthesize G~3~M~9~Gn~2~-P-P-Dol efficiently, a state we operationally term unrestricted LLO synthesis. However, as we already mentioned, brief incubations with low glucose concentrations can hinder extension of undermannosylated intermediates. We categorize conditions such as these, which impede extension of LLO intermediates, as restricted LLO synthesis ([Fig. 1, A](#fig1){ref-type="fig"}). Consequently, the flux of LLO intermediates through the LLO pathway is reduced. We distinguish LLO flux from two other factors, LLO capacity (total LLO that can be synthesized, dependent on availability of Dol-P) and LLO consumption (dependent on transfer of glycan to polypeptide). Deficits in neither capacity nor consumption would be expected to cause LLO intermediates to accumulate. As presented below, restricted conditions were used to determine whether ER stress-activated PERK could compensate for reduced LLO flux. Unrestricted conditions were used to determine whether any such compensation was related to attenuated consumption of LLO, altered LLO capacity, or enhancement of LLO flux. LLOs in cultured cells are conveniently labeled with \[2-^3^H\]mannose. Established solvent extraction procedures can then recover the entire \[^3^H\] LLO pool (i.e., LLO intermediates plus G~3~M~9~Gn~2~-P-P-Dol), or HPLC can be used to examine glycans of individual \[^3^H\] LLOs. Efficient incorporation of \[^3^H\]mannose requires low-glucose medium, resulting in restricted or unrestricted LLO synthesis, depending on the cell type and the glucose concentration.

![**Restricted and unrestricted LLO synthesis, and the effect of CHX.** (A) Hypothetical high-pressure liquid chromatograms of LLO glycans illustrate efficient (unrestricted) synthesis of G~3~M~9~Gn~2~-P-P-Dol versus accumulation of M~2-7~Gn~2~-P-P-Dol intermediates under restricted conditions that simulate metabolic dysfunction. The dashed lines indicate the mannosyl residues that vary in the respective intermediates ([@bib22]). (B) Dermal fibroblasts were treated with the indicated concentrations of CHX for 50 min. Medium with 0.5 mM glucose was used. For the final 20 min, 40 μCi/ml \[^3^H\]mannose was added. \[^3^H\] LLO glycans were isolated and characterized by HPLC. The positions of standards are shown. Note that addition of CHX converts the pattern of LLO glycans from restricted to unrestricted. For comparison, an experiment is shown with 2 mM DTT added for 30 min instead of CHX.](jcb1760605f01){#fig1}

Treatment with cycloheximide (CHX) suggests that translation attenuation can modulate LLO synthesis
---------------------------------------------------------------------------------------------------

As discussed in the Introduction, LLO synthesis in dermal fibroblasts is restricted with 0.5 mM glucose, and ER stress promotes extension of the accumulated LLO intermediates to G~3~M~9~Gn~2~-P-P-Dol. To simulate the contribution of translation attenuation by PERK during the ER stress response we used CHX. We found that mild treatment (4 μM; inhibiting protein synthesis by 25--30%; unpublished data) reduced accumulation of \[^3^H\] LLO intermediates and greatly shifted the LLO profile in favor of \[^3^H\]G~3~M~9~Gn~2~-P-P-Dol ([Fig. 1 B](#fig1){ref-type="fig"}). Treatment with 100 μM CHX (inhibiting translation by ∼50%) caused even greater enhancement, comparable to the effect of 2 mM DTT. Because CHX slows consumption of LLOs for protein N-glycosylation ([@bib14]), we surmise that 4--100 μM CHX may have allowed more time for extension of LLO intermediates, thereby compensating for reduced flux. This also implicated translation attenuation by PERK as a key factor in the ER stress response--mediating extension of undermannosylated intermediates.

Specific activation of PERK\'s kinase activity drives extension of LLO intermediates
------------------------------------------------------------------------------------

To assess PERK\'s potential contribution to LLO synthesis, the transfected CHO-K1 line "Fv2E-PERK" was used. This line expresses a cytoplasmic fusion protein with the PERK kinase domain joined to dual FKBP12-derived domains that bind AP20187, a cell-permeant bifunctional "dimerizer." Such fusion proteins are normally monomers, and are inactive. Addition of dimerizer oligomerizes the Fv2E-PERK fusion proteins, resulting in transautophosphorylation and activation of the kinase domains. The kinase domains then phosphorylate Ser^51^ of eIF2α, inhibiting translation ([@bib33]).

AP20187 caused graded, regulated inhibition of protein synthesis in Fv2E-PERK transfectants, but not untransfected CHO-K1 cells (Fig. S1, available at <http://www.jcb.org/cgi/content/full/jcb.200607007/DC1>). We used 0.5 nM AP20187 (inhibiting protein synthesis by ∼35%) to replicate translation attenuation expected to occur with moderate ER stress. Fv2E-PERK cells underwent restricted LLO synthesis when incubated in 0.3 mM glucose medium for 20 min ([Fig. 2 A](#fig2){ref-type="fig"}), with AP20187 ([Fig. 2 B](#fig2){ref-type="fig"}) causing a robust effect on extension of \[^3^H\] LLO intermediates to \[^3^H\]G~3~M~9~Gn~2~-P-P-Dol. Moreover, N-linked glycans derived from \[^3^H\]G~3~M~9~Gn~2~-P-P-Dol (labeled *x* and *y* in [Fig. 2 \[C and D\]](#fig2){ref-type="fig"}) were sparse under restricted conditions (C), but were increased greatly by AP20187 (D). Thus, moderate translation attenuation by PERK was sufficient to drive extension of LLO intermediates to G~3~M~9~Gn~2~-P-P-Dol, and reestablish correct N-linked glycosylation.

![**PERK\'s kinase activity is sufficient to rectify LLO biosynthetic defects and aberrant N-linked glycosylation.** Fv2E-PERK cells were cultured in the absence (A and C) or presence (B and D) of 0.5 nM AP20187 for 60 min. Incubation with or without AP20187 was then continued for an additional 20 min in medium containing 0.3 mM glucose (causing restricted LLO synthesis), 10% dialyzed FBS, and 40 μCi/ml \[^3^H\]mannose. \[^3^H\] LLO glycans (A and B) and \[^3^H\]N-linked glycans (C and D) were detected by HPLC. The positions of standards are indicated. *x* and *y* indicate N-linked glycans assigned the structures M~9~Gn~2~ and G~1~M~9~Gn~2~, respectively, and thus derived from G~3~M~9~Gn~2~-P-P-Dol rather than undermannosylated LLO intermediates ([@bib45]). Because of low \[^3^H\] labeling in N-glycan experiments, interference from spurious electronic noise was minimized by subjecting HPLC data to root-mean-square smoothing with PSI-Plot V.8 (Poly Software International).](jcb1760605f02){#fig2}

ER stress inducers failed to extend LLO intermediates in the absence of phosphorylatable eIF2α
----------------------------------------------------------------------------------------------

Compared with mouse embryonic fibroblasts (MEFs) expressing normal eIF2α (eIF2α^S51/S51^), MEFs with alanine substitutions at Ser^51^ (eIF2α^A51/A51^) have greatly reduced translation attenuation in response to ER stress because Ser^51^ is phosphorylated by PERK ([@bib40]). Incubation of eIF2α^S51/S51^ or eIF2α^A51/A51^ MEFs with 0.3 mM glucose for 20 min resulted in restricted LLO synthesis ([Fig. 3, A and E](#fig3){ref-type="fig"}). This provided an opportunity to formally demonstrate the role of eIF2α phosphorylation, and therefore translation attenuation, in stimulation of LLO intermediate extension by ER stress. We considered analogous experiments with PERK^−/−^ MEFs, but reasonable conditions causing restricted LLO synthesis were not identified (unpublished data). Rather, in these cells, glucose deprivation diminished G~3~M~9~Gn~2~-P-P-Dol without accumulation of intermediates, with reversal by CHX (Fig. S2, available at <http://www.jcb.org/cgi/content/full/jcb.200607007/DC1>).

![**Acute ER stress does not alter LLO synthesis in eIF2α^A51/A51^ MEFs.** MEFs with two normal eIF2α alleles (eIF2α^S51/S51^; A--D) or two alleles with Ser^51^Ala replacements (eIF2α^A51/A51^; E--H) were cultured in the absence (A and E) or presence of 2 mM DTT for 5 min (B and F), 100 nM TG for 10 min (C and G), or 20 μM CHX for 10 min (D and H). Treatments were then continued for an additional 20 min in medium containing 10% dialyzed FCS, 0.3 mM glucose, and 40 μCi/ml \[^3^H\]mannose. \[^3^H\] LLO glycans were characterized by HPLC, as described for [Fig. 2](#fig2){ref-type="fig"}. The causes of the somewhat different patterns of undermannosylated intermediates in untreated eIF2α^S51/S51^ and eIF2α^A51/A51^ samples in this figure (A and E) and in [Fig. 9](#fig9){ref-type="fig"} are unknown. mRNA samples corresponding to experiments in A--H were tested for splicing of XBP1 mRNA (I). Spliced (XBP1~S~), unspliced (XBP1~U~), and hybrid (XBP1~H~) PCR products are indicated, as well as the sizes (nucleotides) of the XBP1~S~ and XBP1~U~ fragments.](jcb1760605f03){#fig3}

Consistent with prior results with dermal fibroblasts, treatments of eIF2α^S51/S51^ MEFs with DTT (25 min) or TG (30 min) promoted extension of \[^3^H\] LLO intermediates ([Fig. 3, B and C](#fig3){ref-type="fig"}). However, ER stress did not enhance extension in eIF2α^A51/A51^ MEFs ([Fig. 3, F and G](#fig3){ref-type="fig"}), although treatment with 20 μM CHX ([Fig. 3, D and H](#fig3){ref-type="fig"}) demonstrated that the LLO pathway in these cells could respond to translation attenuation. Splicing of XBP1 mRNA is mediated by IRE1, and is a quantitative measure of ER stress ([@bib43]). Assays for this reaction verified that TG and DTT caused robust ER stress with both MEF lines ([Fig. 3 I](#fig3){ref-type="fig"}).

Hence, within the first 30 min of the ER stress response, translation attenuation via eIF2α phosphorylation appears to be the only factor that significantly stimulates extension of LLO intermediates in MEFs.

PERK\'s kinase activity during the ER stress response inhibits G~3~M~9~Gn~2~-P-P-Dol consumption
------------------------------------------------------------------------------------------------

Ostensibly, PERK could aid LLO synthesis if a labile protein inhibited the pathway, or if a stimulatory protein was made upon attenuation of translation initiation ([@bib20]). However, another explanation comes from work by [@bib24], which was extended by us ([@bib14]), showing that under unrestricted conditions of LLO synthesis, the translation inhibitors CHX and puromycin prevent synthesis of \[^3^H\]mannose-labeled G~3~M~9~Gn~2~-P-P-Dol. This is because G~3~M~9~Gn~2~-P-P-Dol consumption is inhibited in the absence of nascent glycoprotein precursor polypeptides, and the G~3~M~9~Gn~2~-P-P-Dol pool does not turn over. Consequently, Dol-P is not regenerated, so new LLO cannot be made with \[^3^H\]mannose. Thus, the results shown in [Figs. 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"} [](#fig2){ref-type="fig"} (under restricted conditions) may be explained by slowed LLO consumption, with more time for extension of undermannosylated intermediates to G~3~M~9~Gn~2~-P-P-Dol.

Two types of measurements were required to determine whether ER stress slows G~3~M~9~Gn~2~-P-P-Dol consumption. For inhibition of G~3~M~9~Gn~2~-P-P-Dol synthesis, metabolic labeling with \[^3^H\]mannose was used. In parallel, to detect unlabeled G~3~M~9~Gn~2~-P-P-Dol, we used fluorophore-assisted carbohydrate electrophoresis (FACE), by which glycans cleaved from LLOs are tagged at their reducing termini with the anionic fluorophore 7-amino-1,3-naphthalenedisulfonic acid (ANDS; [@bib13]). The negatively charged ANDS-glycan conjugates can be separated by electrophoresis with a high-percentage polyacrylamide gel, and detected with ultraviolet light. FACE allows glycans from individual LLO species to be measured quantitatively, and can be used regardless of the medium\'s glucose concentration.

CHO-K1 cells (and CHO-K1--derived Fv2E-PERK cells; see below) underwent unrestricted G~3~M~9~Gn~2~-P-P-Dol synthesis in 0.5 mM glucose medium (Fig. S2 C and not depicted). Synthesis of total \[^3^H\] LLO in CHO-K1 cells with 0.5 mM glucose was inhibited by DTT and TG ([Fig. 4](#fig4){ref-type="fig"}), but no breakdown products were observed (Fig. S2 C). Importantly, no losses of G~3~M~9~Gn~2~-P-P-Dol were detected by FACE ([Fig. 4](#fig4){ref-type="fig"}; increases were apparent, and are explored in Fig. S2 B). PERK\'s activity was sufficient to block G~3~M~9~Gn~2~-P-P-Dol consumption because 10 nM AP20187 strongly inhibited both protein ([Fig. 5, A](#fig5){ref-type="fig"}) and total \[^3^H\] LLO ([Fig. 5, B](#fig5){ref-type="fig"}) synthesis in Fv2E-PERK transfectants, but not in CHO-K1 cells, whereas G~3~M~9~Gn~2~-P-P-Dol detected by FACE was unaffected in all cases ([Fig. 5, C](#fig5){ref-type="fig"}).

![**ER st ress in CHO-K1 cells reduces G~3~M~9~Gn~2~-P-P-Dol consumption.** CHO-K1 cells (∼90% confluent; duplicate 100-mm dishes for \[^3^H\]mannose labeling and duplicate 150-mm dishes for FACE) were incubated with normal medium (10 mM glucose) in the absence or presence of 2 mM DTT (top) or 150 nM TG (bottom) for the indicated times, and then for 20 min (maintaining absence or presence of DTT or TG) in medium with 0.5 mM glucose (unrestricted LLO synthesis). Open symbols: 10 μCi/ml \[^3^H\]mannose was included during the final 20 min, and total \[^3^H\] LLO was determined. As shown in Fig. S2 C, under comparable conditions the majority of radioactivity was incorporated into G~3~M~9~Gn~2~-P-P-Dol. Closed symbols: no \[^3^H\]mannose was included; instead, G~3~M~9~Gn~2~-ANDS was measured by FACE. Data points are averages of duplicates. (insets) FACE gels displaying G~3~M~9~Gn~2~-ANDS from duplicate dishes obtained at the times (minutes) indicated.](jcb1760605f04){#fig4}

![**PERK\'s kinase activity is sufficient to reduce G~3~M~9~Gn~2~-P-P-Dol consumption.** (A--C) Control CHO-K1 (left) or Fv2E-PERK (right) cells were treated without (white bars) or with (black bars) 10 nM AP20187 for 1 h, followed by measurements of \[^3^H\]leucine incorporation into protein (means of quadruplicates ± the SEM; A), measurements of \[^3^H\]mannose incorporation into total LLO (averages of quadruplicates ± the SEM; B), or detection of G~3~M~9~Gn~2~-ANDS by FACE (duplicates; C) in medium with 0.5 mM glucose (unrestricted LLO synthesis under this condition). For A and B, values above the bars are the percentage of incorporation relative to that in the absence of AP20187.](jcb1760605f05){#fig5}

These results show that PERK\'s kinase activity is sufficient to inhibit G~3~M~9~Gn~2~-P-P-Dol consumption under unrestricted conditions, just as it is sufficient to drive extension of undermannosylated intermediates under restricted conditions ([Fig. 2](#fig2){ref-type="fig"}).

PERK is necessary for inhibition of G~3~M~9~Gn~2~-P-P-Dol consumption by ER stress
----------------------------------------------------------------------------------

The necessity of PERK was addressed because IRE1 has also been reported to attenuate translation in response to ER stress ([@bib25]). HeLa S3 cells were transfected with siRNA duplexes directed against distinct regions of PERK mRNA. The PERK-A duplex was ineffective for RNA interference, and was therefore used along with sham transfection as a negative control. The PERK-B duplex efficiently knocked down PERK mRNA (losses of 58 ± 3% with 5 h of transfection and 77 ± 1% with 16 h of transfection). Because some effects on cell viability were noticed with the 16-h transfection, subsequent experiments were done with 5-h transfections. DTT and TG each inhibited synthesis of protein and total \[^3^H\] LLO under unrestricted conditions by about half in sham and PERK-A--treated cells ([Fig. 6, A](#fig6){ref-type="fig"}), whereas the PERK-B duplex fully prevented DTT- and TG-induced translation arrest and \[^3^H\] LLO synthesis inhibition. For reasons that are unclear, DTT treatment tended to elevate total \[^3^H\] LLO labeling in PERK-B--transfected cells above that in nonstressed cells, but the key point is that LLO synthesis was not inhibited. Splicing of XBP1 mRNA (inset) verified that the PERK-B duplex did not prevent DTT or TG from inducing ER stress.

![**Hindering PERK expression by RNA interference or gene disruption prevents inhibition of both protein synthesis and LLO consumption by ER stress inducers.** Metabolic labeling of HeLa S3 and MEF lines was done with 0.5 mM glucose (unrestricted LLO synthesis conditions; HPLC data not depicted). (A) HeLa S3 cells were subjected to sham transfection, or transfection with siRNA duplexes PERK-A or -B for 5 h. Cells were left untreated (control; open bars) or treated with either 100 nM TG for 30 min (striped bars) or 2 mM DTT for 20 min (shaded bars). Synthesis of protein (with \[^3^H\]leucine; left) and LLO (with \[^3^H\]mannose; right) were measured as percentages of the untreated controls. Bars represent means (± the SEM) for 7--8 replicates (protein synthesis) or 8--12 replicates (LLO synthesis) done over 4 independent sets of transfections. (inset) RT-PCR analyses of XBP1 mRNA (representative of 4 independent experiments) from a single gel, cropped for alignment with appropriate bars. Spliced (XBP1~S~), unspliced (XBP1~U~), and hybrid (XBP1~H~) PCR products are indicated, with sizes indicated in [Fig. 3](#fig3){ref-type="fig"}. (B) MEFs with normal alleles (PERK^+/+^; left) or MEFs harboring disrupted PERK alleles (PERK^−/−^; right) were treated with TG or DTT, followed by protein and LLO synthesis measurements, as for A. Bars represent averages (± the SEM) of 3--5 or 6--9 replicates for TG and DTT, respectively, encompassing at least 2 independent experiments.](jcb1760605f06){#fig6}

Because eIF2α−Ser^51^ can be phosphorylated by the kinase PKR in response to double-stranded RNA ([@bib40]), the potential concern over the use of RNA interference was addressed with MEFs bearing two normal PERK alleles (PERK^+/+^) or two disrupted alleles (PERK^−/−^). The results ([Fig. 6 B](#fig6){ref-type="fig"}) confirmed those obtained by RNA interference. Synthesis of protein and total \[^3^H\] LLO under unrestricted conditions were both strongly inhibited by ER stress inducers in the presence, but not the absence, of PERK. XBP1 mRNA splicing assays (unpublished data) verified that DTT and TG induced similarly robust ER stress in both MEF types.

Pulse-chase analysis of LLO flux
--------------------------------

PERK\'s effects on LLO flux might be explained entirely by a compensatory reduction of LLO consumption because PERK activity was replicated by attenuating translation with either CHX ([Fig. 1](#fig1){ref-type="fig"}) or activators of cytoplasmic eIF2α kinases (see the following section). As a more direct test of PERK\'s effect on LLO flux, we performed pulse-chase experiments with Fv2E-PERK cells. After incubation in the absence or presence of AP20187 or DTT, the cells were labeled for 2 min with \[^3^H\]mannose in medium containing 1 mM glucose (which allowed G~3~M~9~Gn~2~-P-P-Dol to be made efficiently, yet permitted sufficient uptake of \[^3^H\]mannose), and then chased in medium lacking \[^3^H\]mannose for up to 10 min. Although several \[^3^H\] species were detected, the only ones confirmed as LLOs (by sensitivity to tunicamycin and comparison with standards) were \[^3^H\]M~5~Gn~2~-P-P-Dol and \[^3^H\]G~3~M~9~Gn~2~-P-P-Dol. Neither LLO was detected during the 2-min pulse (unpublished data). In untreated cells, both \[^3^H\] LLOs were detected after 4 min of chase, and \[^3^H\]G~3~M~9~Gn~2~-P-P-Dol was the only \[^3^H\] LLO significantly detected after 10 min of chase ([Fig. 7, A and B](#fig7){ref-type="fig"}). By comparison, after activation of PERK with AP20187 or introduction of ER stress with DTT, \[^3^H\]G~3~M~9~Gn~2~-P-P-Dol was the predominant LLO detected after 4 min of chase.

![**Pulse-chase analysis of PERK\'s effect on LLO flux.** Fv2E-PERK cells were pulse- labeled with \[^3^H\]mannose for 2 min and chased for up to 10 min, as described in Materials and methods. Cells lacked additional treatments (control) or were treated with either 1 nM AP20187 for 1 h or 2 mM DTT for 20 min before pulse labeling, as well as during the pulse (but not during the chase). The 4-min chase was the earliest point at which \[^3^H\] LLOs were reliably detected. (A) LLO glycans from cells chased for the indicated times were analyzed by HPLC. The positions of M~5~Gn~2~ and G~3~M~9~Gn~2~ are shown by the open and closed arrowheads, respectively. (B) Results from A and a second identically performed experiment were combined (all points are means ± the SEM). HPLC peak heights for M~5~Gn~2~ and G~3~M~9~Gn~2~ were normalized to mannose content, and G~3~M~9~Gn~2~ percentages were calculated. Circles, control; triangles, AP20187; squares, DTT.](jcb1760605f07){#fig7}

These results suggest that PERK may have a direct effect on LLO flux, in addition to the aforementioned compensatory effect on consumption. In contrast, there is no evidence that ER stress affects LLO capacity because in CHO-K1 cells in 10 mM glucose undergoing unrestricted G~3~M~9~Gn~2~-P-P-Dol synthesis (FACE analysis; Fig. S2 B), G~3~M~9~Gn~2~-P-P-Dol quantity was not altered by ER stress (we did notice, however, that 0.5 mM glucose incubation caused an unexpected reduction of G~3~M~9~Gn~2~-P-P-Dol that was reversed by ER stress, perhaps because of reduced consumption). Specific activation of PERK\'s kinase activity in Fv2E-PERK cells with AP20187 also failed to alter G~3~M~9~Gn~2~-P-P-Dol content ([Fig. 5](#fig5){ref-type="fig"}).

Phosphorylation of eIF2α--Ser^51^ explains how cytoplasmic stress inducers counteract abnormalities of LLO biosynthesis and protein glycosylation
-------------------------------------------------------------------------------------------------------------------------------------------------

Eukaryotes contain multiple cytoplasmic eIF2α Ser^51^ kinases distinct from PERK ([@bib40]), suggesting an alternative way to modulate LLO biosynthesis. Arsenite (ARS) and diamide (DIA) induce transcription of the cytoplasmic stress marker HSP70 mRNA, but not the ER stress marker GRP78 mRNA (Table S1, available at <http://www.jcb.org/cgi/content/full/jcb.200607007/DC1>), which is a result opposite to that obtained with ER stress inducers ([@bib42]). By incubating dermal fibroblasts as described for [Fig. 1 B](#fig1){ref-type="fig"}, ARS and DIA greatly enhanced the extension of \[^3^H\] LLO intermediates to G~3~M~9~Gn~2~-P-P-Dol ([Fig. 8, A--C](#fig8){ref-type="fig"}), and diminished N-linked glycoproteins with undermannosylated glycans ([Fig. 8, E--G](#fig8){ref-type="fig"}). Their effects rivaled those of DTT ([Fig. 8, D and H](#fig8){ref-type="fig"}).

![**Treatments with ARS and DIA promote synthesis of G~3~M~9~Gn~2~-P-P-Dol and glycosylation of proteins with G~3~M~9~Gn~2~.** Dermal fibroblasts were untreated (controls; A and E), or treated with 0.2 mM DIA for 20 min (B and F), 40 μM ARS for 1 h (C and G), or 2 mM DTT for 20 min (D and H). Cells were incubated with medium containing 10% dialyzed FBS and 40 μCi/ml \[^3^H\]mannose for 20 min either during (DIA and DTT) or after (ARS) stress treatments. LLO glycans (A--D) and N-linked glycans (E--H) were analyzed by HPLC. The positions of standards are indicated as in [Fig. 2](#fig2){ref-type="fig"}.](jcb1760605f08){#fig8}

Because the effects of ARS and DIA on LLO synthesis correlated with their abilities to inhibit protein synthesis (Figs. S3 and S4, available at <http://www.jcb.org/cgi/content/full/jcb.200607007/DC1>), but not with changes in mannose uptake or hexose-phosphate metabolism (not depicted), the requirement for eIF2α-Ser^51^ phosphorylation was tested with eIF2α^S51/S51^ and eIF2α^A51/A51^ MEFs (as described for [Fig. 3](#fig3){ref-type="fig"}). Disulfiram (DIS), which is another cytoplasmic stress inducer (Table S1), was included. All three agents inhibited protein synthesis in eIF2α^S51/S51^ MEFs ([Table I](#tbl1){ref-type="table"}) by at least half, and robustly promoted extension of \[^3^H\] LLO intermediates ([Fig. 9, A--D](#fig9){ref-type="fig"}). However, their responses were quite disparate in eIF2α^A51/A51^ MEFs. ARS failed to appreciably affect protein ([Table I](#tbl1){ref-type="table"}) or \[^3^H\] LLO ([Fig. 9 G](#fig9){ref-type="fig"}) synthesis in eIF2α^A51/A51^ MEFs, showing that ARS acted mainly through an eIF2α-Ser^51^ kinase, with a specificity comparable to that of DTT ([Fig. 9, E and J](#fig9){ref-type="fig"}). DIA and DIS both inhibited protein synthesis ([Table I](#tbl1){ref-type="table"}) and promoted LLO extension ([Fig. 9, H and I](#fig9){ref-type="fig"}) in eIF2α^A51/A51^ MEFs, but not as well as with eIF2α^S51/S51^ MEFs, indicating that they acted partly through eIF2α-Ser^51^ phosphorylation, and partly through a second means of translation attenuation.

###### 

**Effects of replacing eIF2α^S51^ with eIF2α^A51^ on protein synthesis**

  ----------------------------------------------------------------------------------------------------------------------------------------
  Genotype         Protein Synthesis                                                               
  ---------------- --------------------------------------- --------------------------------------- ---------------------------------------
                   ARS[a](#tblfn1){ref-type="table-fn"}\   DIA[b](#tblfn2){ref-type="table-fn"}\   DIS[c](#tblfn3){ref-type="table-fn"}\
                   (40 μM, 1 h)                            (0.2 mM, 20 min)                        (10 μM, 2 h)

                   *%*                                                                             

  eIF2α^S51/S51^   46.4 ± 2.7                              18.6 ± 0.7                              35.0 ± 0.4

  eIF2α^A51/A51^   93.2 ± 1.6                              66.3 ± 3.9                              83.0 ± 0.9
  ----------------------------------------------------------------------------------------------------------------------------------------

eIF2α^S51/S51^ and eIF2α^A51/A51^ MEFs were treated with stress inducers. Except for the final 5 min, conventional DMEM plus 10% FBS was used. For the final 5 min, DMEM with 0.3 mM glucose, 10% dialyzed FBS, and 5 μCi/ml \[^3^H\]leucine was used. Results are means of triplicates ± the SEM of the percentage of untreated controls. The use of 0.3 mM glucose was not necessary for protein synthesis measurements, but it simplified comparisons with \[^3^H\]mannose-labeling experiments.

[@bib50].

[@bib30].

[@bib11].

![**Importance of eIF2α-Ser^51^ for the actions of cytoplasmic stress inducers on LLO synthesis.** eIF2α^S51/S51^ (A--E) or eIF2α^A51/A51^ (F--J) MEFs ([Fig. 3](#fig3){ref-type="fig"}) were left untreated (CON; A and F) or treated with 40 μM ARS for 1 h (B and G), 0.2 mM DIA for 5 min *(*C and H), 10 μM DIS for 2 h (D and I), or 2 mM DTT for 5 min (E and J). Incubations were continued for 20 min in medium containing the respective agents and 0.3 mM glucose, 10% dialyzed FBS, and 40 μCi/ml \[^3^H\]mannose. \[^3^H\] LLO glycans were analyzed by HPLC as in [Fig. 3](#fig3){ref-type="fig"}.](jcb1760605f09){#fig9}

Collectively, translation attenuation by eIF2α-Ser^51^ kinase activity explains the effects of cytoplasmic stress inducers on LLO synthesis, and represents a merge point with the mechanisms of ER stress inducers.

Discussion
==========

How is the synthesis of G~3~M~9~Gn~2~-P-P-Dol controlled? Evidence exists for regulation of specific reactions in the LLO pathway ([@bib27]; [@bib2]) and for developmental induction of key enzymes ([@bib31]; [@bib6]; [@bib5]). However, mechanisms that might acutely regulate the pathway based on the availability of G~3~M~9~Gn~2~-P-P-Dol have been elusive. Because G~3~M~9~Gn~2~-P-P-Dol is ultimately needed for N-linked glycosylation, and hence ER homeostasis, processes that sense ER stress are candidate regulatory inputs for adjustment of G~3~M~9~Gn~2~-P-P-Dol synthesis.

This study shows that decreased synthesis of polypeptide acceptors by activation of PERK reduces LLO consumption and, consequently, enhances extension of LLO intermediates, replenishing G~3~M~9~Gn~2~-P-P-Dol ([Fig. 10](#fig10){ref-type="fig"}). Because PERK is activated by extended periods of ER stress resulting from hindered G~3~M~9~Gn~2~-P-P-Dol synthesis, and hence, aberrant N-glycosylation ([@bib21]), PERK can balance glycoprotein precursor polypeptide synthesis with LLO pathway flux. Thus, in addition to reducing ER stress by lessening the load of client protein, this mechanism allows PERK to ensure proper N-glycosylation of the polypeptides that continue to be made. The importance of this synergy is emphasized by a recent study showing that maintenance of favorable diffusional properties in the ER lumen is much more dependent on efficient functioning of the lectin-chaperone system (which requires proper N-glycosylation) than the total load of polypeptide ([@bib47]). In addition to decreasing LLO consumption, pulse-chase experiments suggested that PERK stimulates LLO flux itself. The mechanism responsible for this is unclear at this time.

![**Translational balancing by PERK restores correct protein glycosylation.** Symbol and font sizes reflect relative amounts of LLO, protein, and hexose. Arrow thicknesses represent relative activity at each step. Glycans from LLO intermediates are indicated by white squares, with extension to G~3~M~9~Gn~2~ indicated by attachment of black squares. (A) Under normal conditions, LLO intermediates are efficiently extended to G~3~M~9~Gn~2~-P-P-Dol, with proper N-glycosylation. (B) Metabolic dysfunction (for example, by limited hexose supply) reduces flux through the LLO pathway, leading to accumulation of LLO intermediates, incorrect protein glycosylation, ER stress, PERK activation, and phosphorylation of eIF2α. (C) Translational balancing requires only moderate translation attenuation by eIF2α-P. This reduces LLO consumption, allowing LLO intermediates to be extended to G~3~M~9~Gn~2~-P-P-Dol even with metabolic dysfunction. Note that fewer glycoproteins are produced than normal, but they are correctly glycosylated with G~3~M~9~Gn~2~.](jcb1760605f10){#fig10}

Though used here to accumulate undermannosylated intermediates, glucose deprivation may also be a physiological cause of ER stress ([@bib40]). A 30-min reduction of glucose concentration to 2.5 mM (just below the typical fasting level of 4 mM) can cause significant accumulation of LLO intermediates in fibroblasts ([@bib15]). Although the brief (20 min) incubations in low-glucose media used here were insufficient to appreciably inhibit protein synthesis (unpublished data) or cause ER stress ([@bib8]; [@bib42]), seminal studies showed that extended glucose deprivation can trigger an ER stress response, as well as interfere with protein glycosylation ([@bib36]; [@bib46]). In our hands, incubation of dermal fibroblasts for 12 h in medium with 0.5 mM glucose (a restricted condition when used for only 20--30 min) triggered an ER stress response, and both G~3~M~9~Gn~2~-P-P-Dol synthesis and proper protein N-glycosylation were restored ([@bib8]). However, at such extended time-points, UPR-dependent transcription of LLO biosynthetic enzymes ([@bib32]) and increased glucose transport ([@bib8]) would be expected, as well as PERK, to participate in enhancement of G~3~M~9~Gn~2~-P-P-Dol synthesis. Other conditions that interfere with LLO synthesis ([@bib10]; [@bib7]) include exposures to glucosamine and 2-deoxyglucose, which trigger ER stress responses ([@bib36]; [@bib35]; [@bib37]), and to tunicamycin ([@bib31]), which induces ER stress and causes PERK-dependent translation arrest ([@bib21]). In all cases, a compensatory role of PERK would be anticipated.

The vigorous effects of only 20--35% translation attenuation on LLO intermediates were surprising, suggesting influence by translational variations within the physiological range ([@bib40]). The failure to detect acute ER stress effects on LLO synthesis in eIF2α^A51/A51^ MEFs suggests that, absent of translational control, there may be no other strongly stimulatory mechanisms in these cells during the first ∼30 min of the response. This also argues against G~3~M~9~Gn~2~-P-P-Dol metabolism being influenced by potential secondary effects of ER stress (such as misfolding of polypeptide acceptors or disruption of OT). LLO extension in ER stressed-dermal fibroblasts correlated temporally with loss of glycogen and elevation of glucosyl phosphates, suggesting that regulated glycogenolysis might elevate sugar precursor pools and drive LLO extension ([@bib16]). However, a direct link was not established. Given our current results, changes in glycogen metabolism do not appear to have major importance for regulation of LLO synthesis by robust ER stress in MEFs.

The mechanism for PERK reported in this study, termed "translational balancing" in [Fig. 10](#fig10){ref-type="fig"}, does not involve complex ER stress-signaling pathways and may be analogous to regulation by other eIF2α kinases, notably HRI ([@bib17]). Iron deficiency hinders conversion of protoporphyrin IX to heme and releases HRI from its heme-inhibited state to phosphorylate eIF2α-Ser^51^. This, in turn, reduces α- and β-globin chain synthesis to balance hemoglobin synthesis with heme. In addition to reducing undesired malfolded globin chains ([@bib18]), translational balancing should increase heme relative to protoporphyrin. Accordingly, translational balancing may be a simple, general mechanism by which eIF2α-Ser^51^ kinases adjust metabolic pathways whose end products interact with newly synthesized proteins.

Translational control also has implications for the type I congenital disorders of glycosylation (CDG-I), which involve mutations in genes required for G~3~M~9~Gn~2~-P-P-Dol synthesis ([@bib26]; [@bib12]), resulting in aberrant glycosylation of serum proteins. Fibroblasts from CDG-I patients exhibit several criteria of chronic ER stress, suggesting that their LLO defects may be partially offset by beneficial effects of the ER stress response ([@bib32]). CDG-I may be amenable to correction, as G~3~M~9~Gn~2~-P-P-Dol production is not completely impaired because of the presence of at least one partially active allele. Because Ib is the only treatable subtype of the 12 CDG-Is (a--l; [@bib34]), the compensatory effects of DIS ([Fig. 9](#fig9){ref-type="fig"}) are particularly interesting. DIS is a clinically approved drug used to discourage alcoholism ([@bib11]), and is innocuous unless alcohol is consumed. Though toxic, ARS also has a history of therapeutic use ([@bib29]). In preliminary experiments with CDG-Ia fibroblasts, we noted that DIS, ARS, and DIA all had some ability to restore synthesis of G~3~M~9~Gn~2~-P-P-Dol, although the effects were highly variable (unpublished data), advocating further development of such agents.

In conclusion, we find that PERK can balance ER glycoprotein synthesis with flux through the G~3~M~9~Gn~2~-P-P-Dol pathway. Upon accumulation of LLO intermediates, aberrant N-linked glycosylation would create ER stress and activate PERK. PERK\'s kinase activity would then reduce the load of glycoprotein precursor polypeptides, slow LLO consumption, facilitate extension of LLO intermediates to G~3~M~9~Gn~2~-P-P-Dol, and reestablish correct N-linked glycosylation.

Materials and methods
=====================

Reagents and cell cultures
--------------------------

All stress inducers were obtained from Sigma-Aldrich. An ARGENT Regulated Homodimerization kit containing AP20187 was a gift from Ariad Pharmaceuticals ([www.ariad.com/regulationkits](www.ariad.com/regulationkits)). \[2-^3^H\]mannose (15 Ci/mmol) and \[^3^H\]leucine (164 Ci/mmol) were purchased from GE Healthcare. Cell culture media were obtained from Invitrogen, and sera were obtained from Atlanta Biologicals. CHO-K1 ([@bib3]), PERK-Fv2E--expressing CHO-K1 transfectants ([@bib33]), PERK^+/+^ and PERK^−/−^ MEFs ([@bib21]), eIF2α^S51/S51^ and eIF2α^A51/A51^ MEFs ([@bib40]), HeLa S3 ([@bib9]), and dermal fibroblasts ([@bib8]; [@bib42]) were obtained and grown in the culture media described. However, to aid adhesion, MEFs were grown on standard 100-mm tissue culture dishes pretreated with 10 ml autoclaved 0.1% type B bovine gelatin (Sigma-Aldrich) for at least 1 h. After removal of the solution, the dishes were dried for at least 30 min.

Analysis of LLO glycans and N-linked glycans by \[^3^H\]mannose incorporation
-----------------------------------------------------------------------------

Cell cultures were incubated (see previous section) for 20--30 min (except for [Figs. 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}; 5 min) in media with 0.3--0.5 mM glucose containing 10% dialyzed FBS and \[2-^3^H\]mannose. \[^3^H\] LLOs were extracted with chloroform/methanol/water (10:10:3). Either the total LLO-associated tritium was measured by liquid scintillation spectroscopy or the \[^3^H\] LLOs were treated with weak acid to release water-soluble glycans, which were then fractionated and detected by HPLC with in-line liquid scintillation spectroscopy ([@bib8]; [@bib45]). The HPLC system resolves glycans on the basis of single-sugar differences, with the largest glycans eluting the latest. The proteinaceous pellets remaining after organic extraction were digested with pronase and N-glycanase (Calbiochem), and the released N-glycans were analyzed by HPLC ([@bib45]).

For LLO pulse-chase studies with Fv2E-PERK cells, both \[^3^H\]mannose and \[^3^H\]glucosamine were evaluated, but only \[^3^H\]mannose was deemed suitable. Conditions were optimized by varying the times and \[^3^H\]mannose concentrations for pulse labeling. In most \[^3^H\]mannose pulses, we detected multiple species eluting from the HPLC column earlier than 20 min, but these were disregarded because they were refractory to inhibition by tunicamycin (an inhibitor of LLO synthesis). For the experiment presented in [Fig. 7](#fig7){ref-type="fig"}, Fv2E-PERK cells were incubated in F-12 medium with 10% dialyzed FBS, 1.0 mM glucose, and 250 μCi/ml \[^3^H\]mannose for 2 min. Labeling was then terminated by removal of \[^3^H\] medium and addition of methanol (no chase), or cells were washed twice with prewarmed phosphate-buffered saline, and the incubation continued in the same medium, but without \[^3^H\]mannose before terminating the reactions (chase). LLOs were recovered from methanolic suspensions in sequential chloroform/methanol (2:1) and chloroform/methanol/water (10:10:3) extracts, which were combined for recovery of all LLO species, and processed for HPLC as described in the previous paragraphs.

Analysis of LLO glycans by FACE
-------------------------------

LLO glycans from unlabeled cells were recovered by techniques described in the preceding section, coupled to ANDS, and analyzed with FACE oligosaccharide profiling gels. Gel images were acquired with a Fluor-S MultiImager (Bio-Rad Laboratories) using a 530DF60 filter. When necessary, individual ANDS conjugates were quantified with Quantity One software supplied with the scanner ([@bib13]). For clarity, some images were adjusted with brightness and contrast tools in PowerPoint 2003 (Microsoft), treating all data from a single gel identically. Cropping and joining of lanes in a single gel is indicated by vertical lines. For critical direct comparisons, only samples loaded on the same FACE gel were considered. This limited most experiments to duplicate determinations. Thus, we present original FACE data for the reader\'s inspection. Per 10^7^ cells, 50% of the sample was usually loaded per gel lane.

Protein synthesis assays
------------------------

Incorporation of \[^3^H\]leucine into total protein involved incubation in media with 10% dialyzed FBS and 5 μCi/ml \[^3^H\]leucine for 5 min, collection of the material insoluble in 5% trichloroacetic acid ([@bib44]), and determination of tritium by liquid scintillation spectroscopy. Incorporation of 125 μCi/ml \[^35^S\]methionine for 20 min was done exactly as described ([@bib42]) by phosphorimager analysis of polyacrylamide gels. We have not noticed any differences in the validity or reliability of these two assays.

Application of siRNAs
---------------------

siRNA duplexes targeting human PERK (accession no. [NM_004836](NM_004836)) were PERK-A (sense 5′-CAAGAGGAAGACAUCCUGCtt-3′, antisense 5′-GCAGGAUGUCUUCCUCUUGtt-3′) and PERK-B (sense 5′-UGGACCAUGAGGACAUCAGtt-3′, antisense 5′-CUGAUGUCCUCAUGGUCCAtt-3′), corre- sponding to coding region nucleotides 691--709 and 2,237--2,255, respectively (synthesized by the RNA Oligonucleotide Synthesis Core of University of Texas Southwestern Medical Center). Individual oligonucleotides were resuspended in 500 μl DEPC-treated H~2~O (concentrations determined by OD~260~), mixed, and diluted to 20 μM each in annealing buffer (100 mM potassium acetate, 30 mM Hepes-KOH, pH 7.4, and 2 mM magnesium acetate), heated for 3 min at 90°C, and incubated for 1 h at 37°C to form duplexes. HeLa S3 cells were plated in DME with 10% FBS without antibiotics in 60-mm dishes, and used at ∼30--50% confluence. Transfection of siRNAs was done with Oligofectamine (Invitrogen) according to the manufacturer\'s instructions. Cells were incubated with buffer only ("sham") or with duplexes for 5 or 16 h. Cells were passaged once into the desired numbers of 100-mm dishes. 3 d after the initiation of transfection, cells were treated with the stress inducers indicated or used to harvest RNA. PERK mRNA was quantified by northern analysis and normalized to actin mRNA ([@bib42]).

Splicing of XBP1 mRNA
---------------------

Total mRNA was isolated with a RNeasy Mini kit (QIAGEN). Splicing of XBP1 mRNA was assessed by RT-PCR ([@bib43]). PCR products representing spliced XBP1 (XBP1~S~), unspliced XBP1 (XBP1~U~), and a hybrid (formed during the chain reaction, composed of one strand each of XBP1~U~ and XBP1~S~, \[XBP1~H~\]) were resolved by agarose gel electrophoresis.

Online supplemental material
----------------------------

Fig. S1 shows the inhibition of protein synthesis in Fv2E-PERK cells by AP20187. Fig. S2 shows ancillary LLO analyses. Fig. S3 shows the inhibition of protein synthesis by cytoplasmic stress inducers. Fig. S4 shows the recovery from DIA treatment. Table S1 shows mRNA responses in dermal fibroblasts for cytoplasmic stress inducers. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200607007/DC1>.

We thank Dr. Joel Goodman for valuable comments on the manuscript, and Mr. Biswanath Pramanik for assistance with cell culture.

We acknowledge generous support from the National Institutes of Health (GM38545 to M.A. Lehrman; DK42394 to R.J. Kaufman; DK47119 and ES08681 to D. Ron) and the Robert Welch Foundation (I-1168 to MAL).

[^1]: Correspondence to Mark A. Lehrman: <mark.lehrman@utsouthwestern.edu>
